1.83
Schlusskurs vom Vortag:
$2.00
Offen:
$2.03
24-Stunden-Volumen:
1.57M
Relative Volume:
0.69
Marktkapitalisierung:
$74.57M
Einnahmen:
$68.68M
Nettoeinkommen (Verlust:
$-60.84M
KGV:
-1.1438
EPS:
-1.6
Netto-Cashflow:
$-38.42M
1W Leistung:
+17.31%
1M Leistung:
-0.54%
6M Leistung:
-51.46%
1J Leistung:
-70.81%
Pulmonx Corp Stock (LUNG) Company Profile
Firmenname
Pulmonx Corp
Sektor
Branche
Telefon
650-364-0400
Adresse
700 CHESAPEAKE DRIVE, REDWOOD CITY
Vergleichen Sie LUNG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
LUNG
Pulmonx Corp
|
1.83 | 81.49M | 68.68M | -60.84M | -38.42M | -1.60 |
|
ABT
Abbott Laboratories
|
123.84 | 214.96B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.59 | 149.24B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
358.16 | 136.23B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
90.20 | 116.33B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
83.07 | 48.41B | 5.88B | 1.34B | 577.90M | 2.3455 |
Pulmonx Corp Stock (LUNG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-31 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-03-10 | Eingeleitet | D. Boral Capital | Buy |
| 2024-12-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2024-06-04 | Eingeleitet | Lake Street | Buy |
| 2024-02-23 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-05 | Eingeleitet | Craig Hallum | Buy |
| 2023-02-27 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-01-03 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-12-12 | Hochstufung | Citigroup | Neutral → Buy |
| 2022-07-11 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-03-02 | Fortgesetzt | BofA Securities | Neutral |
| 2021-12-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2021-04-01 | Eingeleitet | Citigroup | Buy |
| 2021-03-25 | Eingeleitet | Piper Sandler | Neutral |
| 2021-03-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-01-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2020-10-26 | Eingeleitet | BofA Securities | Buy |
| 2020-10-26 | Eingeleitet | Canaccord Genuity | Buy |
| 2020-10-26 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2020-10-26 | Eingeleitet | Stifel | Buy |
| 2020-10-26 | Eingeleitet | Wells Fargo | Equal Weight |
Alle ansehen
Pulmonx Corp Aktie (LUNG) Neueste Nachrichten
A better buy-in window may exist right now for Pulmonx Corp (LUNG) - setenews.com
Will Pulmonx Corporation stock maintain momentum in 20252025 Sector Review & Safe Entry Point Alerts - newser.com
Can Pulmonx Corporation stock outperform in 2025 bull market2025 Analyst Calls & Weekly High Momentum Picks - newser.com
Technical signs of recovery in Pulmonx Corporation2025 Price Action Summary & Weekly Stock Performance Updates - newser.com
Visualizing Pulmonx Corporation stock with heatmapsWeekly Trade Analysis & Free Risk Controlled Daily Trade Plans - newser.com
What catalysts could drive Pulmonx Corporation stock higherEarnings Performance Report & Low Volatility Stock Recommendations - newser.com
Using data filters to optimize entry into Pulmonx CorporationJuly 2025 Trends & Target Return Focused Stock Picks - newser.com
Pulmonx Shares Surge on Leadership Shakeup and Upbeat Forecast - AD HOC NEWS
Is Pulmonx Corporation (LUNG) One of the Best Stocks Under $3 to Invest In? - Insider Monkey
Is Pulmonx Corporation reversing from oversold territoryWeekly Trade Report & Weekly High Potential Stock Alerts - newser.com
Historical volatility pattern of Pulmonx Corporation visualizedChart Signals & High Accuracy Swing Trade Signals - newser.com
Why Pulmonx Corporation stock remains on watchlistsJuly 2025 Sentiment & Accurate Technical Buy Alerts - newser.com
Is this a good reentry point in Pulmonx CorporationJuly 2025 Snapshot & Daily Profit Focused Screening - newser.com
Pulmonx (NASDAQ:LUNG) Given New $14.00 Price Target at D. Boral Capital - MarketBeat
Pulmonx (LUNG) Anticipates Q3 Revenue of $21.5 Million - GuruFocus
What hedge fund activity signals for Pulmonx Corporation stockRecession Risk & Daily Profit Maximizing Tips - newser.com
Tick level data insight on Pulmonx Corporation volatilityMarket Activity Summary & Entry Point Strategy Guides - newser.com
Lake Street Lowers Price Target for Pulmonx (LUNG) Amidst Mainta - GuruFocus
LUNG’s Surprise Revenue Surge: Key Factors - StocksToTrade
Pulmonx brings back former CEO amid leadership shakeup - Investing.com India
Pulmonx Corp (LUNG) Q3 2025 Earnings Report Preview: What To Expect - Yahoo Finance
Pulmonx Corp (LUNG) Q3 2025 Earnings Report Preview: What To Exp - GuruFocus
Canaccord Genuity reiterates Buy rating on Pulmonx stock amid leadership changes - Investing.com Nigeria
Using Python tools to backtest Pulmonx Corporation strategiesDip Buying & Fast Gain Stock Tips - newser.com
D. Boral Capital Maintains Pulmonx (LUNG) Buy Recommendation - Nasdaq
Nucor To Rally More Than 14%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga
Analyst Lowers Price Target for Pulmonx (LUNG) While Maintaining Buy Rating | LUNG Stock News - GuruFocus
Pulmonx brings back former CEO amid leadership shakeup By Investing.com - Investing.com Australia
How Pulmonx Corporation stock compares to market leaders2025 Breakouts & Breakdowns & High Conviction Trade Alerts - newser.com
Healthcare Rally: Pulmonx, UHS, And X4 Lead After-Hours Gains Amid Strategic Updates - Nasdaq
Pulmonx Corp (LUNG) Q3 2025 Earnings: Revenue Surpasses Estimates at $21.5 Million - GuruFocus
LUNG to Discuss Q3 2025 Results and Annual Outlook in November C - GuruFocus
Pulmonx Announces Leadership Changes with New CEO - TipRanks
Pulmonx announces management transition and preliminary third quarter 2025 revenue reschedules third quarter 2025 earnings call to November 12, 2025 - MarketScreener
Pulmonx Announces Management Transition And Preliminary Third Quarter 2025 Revenue Reschedules Third Quarter 2025 Earnings Call To November 12, 2025 - TradingView
Pulmonx Corporation Announces Leadership Transition and Preliminary Third Quarter 2025 Revenue Estimates - Quiver Quantitative
Pulmonx Announces Management Transition and Preliminary Third Quarter 2025 Revenue; Reschedules Third Quarter 2025 Earnings Call to November 12, 2025 - The Manila Times
Pulmonx Corporation Announces CEO Changes, Effective October 27, 2025 - MarketScreener
Pulmonx (Nasdaq: LUNG) reappoints Glen French as CEO; preliminary Q3 revenue ~$21.5M - Stock Titan
Finanzdaten der Pulmonx Corp-Aktie (LUNG)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):